RE:RE:RE:RE:RE:RE:Comments on IMV MV: Friday (now today May 18, 2018)) and next week look to be more gains for the outpacing shares of this Halifax lab. IMV — formerly Immunovaccine.
“Abstracts,” or summaries, are just published for the annual ASCO cancer gathering in Chicago (early June). IMV’s abstract summarizes developments at the Halifax lab’s headline ovarian cancer clinical trials (with Incyte’s epacadostat drug).
https://abstracts.asco.org/214/AbstView_214_228043.html
For investors who “care” about the science, the online material from ASCO’s scores of abstracts are a pathway through the hype, paid promotions and sometimes, bogus analyst reports proliferating about success rates for dozens of pub-cos’ several cancer and infectious disease initiatives.
https://abstracts.asco.org/214/CatView_214_B.html
The IMV team (Olga Hrytsenko, Marianne Stanford, Oliver Dorigo and others) notes in its summary: “DPX-Survivac induces systemic survivin-specific T cell responses. T cells were demonstrated to migrate into tumors and correlated with objective clinical responses to combination therapy.”
Why ASCO?
June 3 at the American Society of Clinical Oncologists meeting in Chicago. This is the most widely attended scientific cancer conference of the year.
— 6,700 applications for oral presentations for 100 slots this year. IMV is one of the 100 — to present data from the “Incyte” ovarian cancer trial. The presenter will be Oliver Dorigo, head of the ovarian cancer unit at Stanford University here in northern California
Oliver Dorigo — Dr. Dorigo‘s presentation –please see abstract of his presentation on ASCO conference website — you will recall the that IMV staged in midtown Manhattan a few weeks ago. “I’ve been working in this field of ovarian cancer for 25 years, and we have never seen anything like this kind of T-cell response.”
— The ASCO abstract suggests 9 of 10 of those treated in a low-dose cohort showed improvement.
There are some in the crowded field of immunotherapy — using one’s immune system to counteract tumors and cancer infiltration of the body — that nothing like this has ever been achieved in cancer therapy in late-stage patients.
The original clinical trial results unveiled in the low-dose cohort in December 2017 are the same patients as these to be referenced. Their condition continues to improveT. he longer the time from initial treatment, the better the results. 2018-05-18
I added yet again Wednesday to our stockpile of IMMVD shares (about $700,000 USD worth now and owned for three years in June). IMV shares in Toronto and in USA rose 7 percent to a new high today.
IMV shares will begin trading as a full-fledged NASDAQ stock in USA in early to mid-June (my estimate). Let’s hope we won’t see paid promotion masquerading as editorial for IMV, formerly Immunovaccine. The immuno-therapy company does not need to “raise” cash right now and almost surely will benefit from scientific journals and international media coverage that track its clinical progress across cancer, infectious disease and rabies. (www.imvaccine.com)
Frederic Ors, CEO of IMV Those suffering the rapid gutting and shortened life from ovarian cancer tumors, and regarding other IMV trials — lymphoma, RSV respiratory viruses, HPV virus and certain infectious diseases — will gain from any interaction with the immuno-therapies that IMV is developing.
Dana-Farber Cancer Institute just outside Boston is partnering with IMV for fresh applications that use IMV’s DepoVax-Survivac methodology. (Leidos, a healthcare consulting company with USA government ties, spun off from Lockheed-Martin, is working with IMV in the area of infectious diseases.)
For the art of the possible, or what is possible, in the ASCO (American Society of Clinical Oncology) data-preview arena each year regarding cancer treatments, please take a look today at a $4 billion company, LOXO Oncology, and its breast-cancer abstract for the conference. LOXO is the ticker in USA.
IMV shares (IMMVD in USA and IMV in Canada) appear to be on track to set fresh highs into the close of May and perhaps ahead of a NASDAQ listing. We’ll see.
GorgeousGeorge1 wrote: Can anyone repost that cut and paste coherently please? Whenever I post from my phone this website takes out all spacing. https://thomcalandra.com/markers-of-success-imv-wrn/